|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2004-5-26
|
|
pubmed:abstractText |
Immunostimulating complex (ISCOM) vaccines are particulate antigen delivery vehicles composed of saponin, cholesterol, phospholipid and immunogen. Here we illustrate that ISCOM-based vaccines represent an attractive modality for the development of anti-cancer vaccines. Using murine models and a model cancer antigen, ISCOM vaccines were shown to induce potent CD8 T cell responses, to mediate protection in three different tumor models, to promote Th1-biased immunity, and to induce CD8 T cell responses in the absence of CD4+ T cell help. The former three activities were also found to be substantially improved when the vaccine antigen was associated with the ISCOM structure. Furthermore, the presence in vivo of pre-existing antibodies against the vaccine antigen did not inhibit CD8 T cell induction by the ISCOM vaccine. Although vaccination was effective against challenge with vaccine-antigen expressing tumors, no activity against neighboring vaccine-antigen negative tumor cells was observed, indicating that determinant spreading or bystander activity does not lead to significant anti-cancer activity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0264-410X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
25
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
963-74
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15161073-Animals,
pubmed-meshheading:15161073-Antibodies, Neoplasm,
pubmed-meshheading:15161073-Antigens, Neoplasm,
pubmed-meshheading:15161073-CD8-Positive T-Lymphocytes,
pubmed-meshheading:15161073-Cancer Vaccines,
pubmed-meshheading:15161073-Carcinoma, Lewis Lung,
pubmed-meshheading:15161073-Epitopes,
pubmed-meshheading:15161073-Female,
pubmed-meshheading:15161073-ISCOMs,
pubmed-meshheading:15161073-Immunoglobulin G,
pubmed-meshheading:15161073-Injections, Subcutaneous,
pubmed-meshheading:15161073-Melanoma, Experimental,
pubmed-meshheading:15161073-Mice,
pubmed-meshheading:15161073-Mice, Inbred BALB C,
pubmed-meshheading:15161073-Mice, Inbred C57BL,
pubmed-meshheading:15161073-Mice, Knockout,
pubmed-meshheading:15161073-Ovalbumin,
pubmed-meshheading:15161073-Time Factors,
pubmed-meshheading:15161073-Vaccination
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
ISCOM based vaccines for cancer immunotherapy.
|
|
pubmed:affiliation |
Cooperative Research Center for Vaccine Technology, Queensland Institute of Medical Research and the University of Queensland, Queensland 4029, Australia.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
